UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Spero Therapeutics (Nasdaq: SPRO), a clinical-stage biopharmaceutical company specializing in rare diseases and multi-drug resistant bacterial infections treatments, has announced its participation in the TD Cowen 45th Annual Health Care Conference.

The conference will take place in Boston from March 3rd to 5th, 2025, where Esther Rajavelu, Spero's Interim President and CEO, will present and be available for one-on-one meetings. Interested parties can access the presentation webcast through Spero Therapeutics' website under the 'Events and Presentations' section, with a replay available after the event.

02/25/2025 - 10:15 AM

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu, Spero’s Interim President and Chief Executive Officer, management will present and will be available for one-on-one meetings at the TD Cowen 45^th Annual Health Care Conference being held in Boston, March 3^rd – 5^th, 2025. Details are as follows:

TD Cowen 45^th Annual Health Care Conference
Company presentation:	Tuesday March 4, 2025
Time:	3:10 PM ET

To request a meeting or for more details about the conferences please reach out to your institutional contact.

The webcast may also be accessed through Spero Therapeutics’ website (www.sperotherapeutics.com) on the “Events and Presentations” page under the “Connect” tab. A replay will be available on the website following the conclusion of the event.

About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and MDR bacterial infections.
For more information, visit https://sperotherapeutics.com.

Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@Sperotherapeutics.com

Media Inquiries:
media@sperotherapeutics.com

FAQ

When and where is Spero Therapeutics (SPRO) presenting at the TD Cowen Healthcare Conference 2025?

Spero Therapeutics will present at the TD Cowen Healthcare Conference in Boston from March 3rd to 5th, 2025.

How can investors access Spero Therapeutics' (SPRO) TD Cowen conference presentation?

Investors can access the webcast through Spero Therapeutics' website (www.sperotherapeutics.com) under 'Events and Presentations' page, with replay available post-event.

What is Spero Therapeutics' (SPRO) current business focus?

Spero Therapeutics is a multi-asset clinical-stage biopharmaceutical company focused on developing treatments for rare diseases and multi-drug resistant bacterial infections.